The experimental inflammation drug was seen as having 'pipel...

The experimental inflammation drug was seen as having 'pipeline-in-a-product' potential, meaning it could be effective in treating a range of conditions. However, the recent clinical hold by the FDA could significantly impact the development and potential of zelnecirnon.